TW544448B - Pyridine derivatives - Google Patents

Pyridine derivatives Download PDF

Info

Publication number
TW544448B
TW544448B TW087110887A TW87110887A TW544448B TW 544448 B TW544448 B TW 544448B TW 087110887 A TW087110887 A TW 087110887A TW 87110887 A TW87110887 A TW 87110887A TW 544448 B TW544448 B TW 544448B
Authority
TW
Taiwan
Prior art keywords
methyl
phenyl
group
alkyl
hydrogen
Prior art date
Application number
TW087110887A
Other languages
English (en)
Inventor
Hans Allgeier
Yves Auberson
Michel Biollaz
Nicholas David Cosford
Fabrizio Gasparini
Original Assignee
Novartis Ag
Sibia Neurosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=27128958&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=TW544448(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Novartis Ag, Sibia Neurosciences Inc filed Critical Novartis Ag
Application granted granted Critical
Publication of TW544448B publication Critical patent/TW544448B/zh

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/06Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02Muscle relaxants, e.g. for tetanus or cramps
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/08Antiepileptics; Anticonvulsants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/22Anxiolytics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/24Antidepressants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • A61P9/10Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/06Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom
    • C07D213/16Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom containing only hydrogen and carbon atoms in addition to the ring nitrogen atom containing only one pyridine ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/26Radicals substituted by halogen atoms or nitro radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/28Radicals substituted by singly-bound oxygen or sulphur atoms
    • C07D213/30Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/46Oxygen atoms
    • C07D213/50Ketonic radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/52Sulfur atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/44Radicals substituted by doubly-bound oxygen, sulfur, or nitrogen atoms, or by two such atoms singly-bound to the same carbon atom
    • C07D213/53Nitrogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/55Acids; Esters
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/56Amides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/24Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D213/54Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/57Nitriles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62Oxygen or sulfur atoms
    • C07D213/63One oxygen atom
    • C07D213/65One oxygen atom attached in position 3 or 5
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/72Nitrogen atoms
    • C07D213/74Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79Acids; Esters
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/79Acids; Esters
    • C07D213/80Acids; Esters in position 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81Amides; Imides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/81Amides; Imides
    • C07D213/82Amides; Imides in position 3
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/78Carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C07D213/84Nitriles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D213/00Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/89Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members with hetero atoms directly attached to the ring nitrogen atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D215/00Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
    • C07D215/02Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
    • C07D215/12Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D239/00Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/02Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings
    • C07D239/24Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members
    • C07D239/28Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings not condensed with other rings having three or more double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D239/30Halogen atoms or nitro radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D319/00Heterocyclic compounds containing six-membered rings having two oxygen atoms as the only ring hetero atoms
    • C07D319/101,4-Dioxanes; Hydrogenated 1,4-dioxanes
    • C07D319/141,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems
    • C07D319/161,4-Dioxanes; Hydrogenated 1,4-dioxanes condensed with carbocyclic rings or ring systems condensed with one six-membered ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/28Halogen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D401/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/10Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D409/00Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07FACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
    • C07F7/00Compounds containing elements of Groups 4 or 14 of the Periodic System
    • C07F7/02Silicon compounds
    • C07F7/08Compounds having one or more C—Si linkages
    • C07F7/0803Compounds with Si-C or Si-Si linkages
    • C07F7/081Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te
    • C07F7/0812Compounds with Si-C or Si-Si linkages comprising at least one atom selected from the elements N, O, halogen, S, Se or Te comprising a heterocyclic ring

Description

544448 A7 B7 五、發明説明(1 ) 一 本發明係關於2 -芳基鏈知基-、2 -雜芳基鍵晞基-、2 -芳 基鏈炔基·、2-雜芳基鏈炔基-、2_芳基偶氮-和2-雜芳基偶 氮·吨淀於緩和TT1GluR類活性及於治療mGluR5媒介疾病方 面 < 使用’係關於用於這些治療的藥用組合物上之使用, 及係關於新頭的2 -芳基鏈晞基、2 -雜芳基鏈婦基、2 _芳基 鏈炔基、2 -雜芳基鏈炔基、2 -芳基偶氮_和2 -雜芳基偶氮_ p比咬。 已經發現到2 -芳基鏈~基、2 -雖芳基缝晞基、2 -芳基鍵 块基、2 -雜芳基鏈炔基、2 -芳基偶氮-和2 -雜芳基偶氮-吡 啶(包括藥用可接受的鹽類)(下文稱爲本發明之物劑)可作 爲mGluR的緩和劑。tnGluR的緩和作用由幾種方式得到證 實,尤其是在結合分析及官能性分析(如:第二個信使分析 或測定細胞間妈濃度變化)°舉例言之,表達mGluR5 a之測 定重組細胞鏈中的肌醇反轉顯示本發明之選定物劑的I C 5 () 約1 η Μ /升至約5 0 " Μ /升。 經滴部中央標準局員工消費合作社印繁 特別地,本發明之物劑具有價値的藥用性質。例如,它 們在人體代謝谷胺酸鹽受體(mGluR)具有顯著及選定的緩 和(特別是拮抗)作用。此可由活體外測定,如:於重組的 人體代謝谷胺酸鹽受體(特別是丼與P L C _偶合的次類, 如:mGluR5 )的例子中,使用不同程序(如:根據L.P. Dagget 等人,Neuropharm.,34., 871-886 (1995), P.J. Flor 等人,J. Neurochem.,67, 58-63 (1996))測定拮抗誘發細 胞間C a2濃度提高之抑制作用,或者由丁. Knoepfel等人, J. Pharmacol.,288, 389-392 (1994),L.P. Daggett 等人, -4 - 本纸張尺度適用中國國家標準(CNS ) A4規格(210X 297公釐) 544448 Α7 Β7 五、發明説明(2 ) 請 閱 讀 背 面 之 注-意 事 項 4 'Α 舄 % 頁
Neuropharm·,5 8-73 ( 1996 )及所列的文獻所述測定拮抗 誘導的肌醇磷酸鹽反轉受到抑制的程度。人體mGluR次類 的隔離和表示述於US Patent No. 5,52 1,297 °本發明選定 的物劑在重組細胞中之抑制奎思奎特(qUisqUalate )誘發的 肌醇磷酸鹽反轉的[C5G値顯示hmGluR5a約Ί nM /升至約 50" M/升。 據此,本發明係關於本發明之物劑於治療與谷胺酸訊息 傳遞不規則有關的失調方面之使用及於與完全或部分由 mGluR5媒介的神經系統失調方面之使用。 與谷胺酸-訊息傳遞不規則有關的疾病如:癲癇、大腦局 邵貧血(特別是急性貧血)、眼部貧血疾病、肌肉抽筋(如: 局部或全部抽筋),及特別是驚風或疼痛。 元全或邶分由mGluR5媒介的神經系統失調如:神經系統 的急性外傷和慢性退化、精神病和疼痛。 4 本發明亦係關於本發明的物劑於治療與谷胺酸訊息傳遞 不規則有關的失調方面之使用,及治療完全或部分由第丨類 mGluR媒介的神經系統失調方面之使用。 經濟部中央標準局員工消費合作社印繁 此外,本發明係關於本發明之物劑於製造用以治療與谷 胺酸訊息傳遞不規則有關的失調及治療完全或部分由第;^類 mGluR媒介的經系統失調之藥用組合物方面之使用。 本發明的另一特點係關於及治療完全或部分由第工類 mGluR(以mGluR5爲佳)媒介的神經系統失調的方法,此方 法包含在需要此治療的溫血生物上施用療效量的本發明之 物劑。 ______ - 5 -___ 本紙張尺度適用中國國家標準(CNS ) A4規格21 〇χ 297公釐)~ " ----. ---- 544448 A7 B7 _ __-_ -__ ~——一 ______—— 五、發明説明(3 ) 另一特點中,本發明係關於新穎的2 ·芳基鏈烯基-、2 -雜 芳基鏈締基-、2 -芳基鏈決基-、2 -雜芳基鏈炔基·、2 -芳基 偶氮-和2-雜芳基偶氮-吡啶及它們的鹽類及其製法。 此外,本發明係關於一種藥用組合物,包含藥用活性成 物及慣用的藥用賦形劑、新穎的2 -芳基鏈烯基-、2 -雜芳 基鏈晞基-、2-芳基鏈決基-、2-雜芳基鏈炔基-、2-芳基偶 氮-和2 -雜芳基偶氮-吡啶或其於藥用上可被接受的鹽類。 本發明的物劑如式I化合物 凡 (請先閱讀背面之注意事項存填寫本頁)
其中, 經濟部中央標準局員工消費合作社印紫 R 1代表氫、低碳烷基、經基-低碳燒基、低瘦燒基-胺 基、旅νί定基、幾基、醋化的叛基、廳:胺化的幾基、不 飽和或經低%。fe基"、低Ί氣基-、卣基-和//或三氣 曱基-取代的N -低碳烷基-N -苯基胺基甲醯基、低碳烷 氧基、鹵基-低碳坑基或1¾基-低緩fe氧基, R 2代表氫、低碳烷基、羧基、酯化的羧基、醯胺化的羧 基、經基-低壤紀基、經基、低碳號氧基或低碳燒醯:氧 基、4-(4 -氣-卞S’S基)-旅咬-i -基複基、4 -第三丁氧基 幾基-泰唤-丨-基·致基、4 - ( 4 - ®氮基-2 -幾基爷gg基)_ -6 - 本紙張尺度適用中國國家標準(CNS ) Α4規格(210x 297公釐) 544448 A7 B7 經滴部中央標率局員Η消費合作社印繁 五、發明説明(4 ) 哌嗉_ 1 -基-羧基或4 - ( 4 -疊氮基-2 -羥基-3 -碘·芊醯 基)-旅17秦-〗_基複基’ R 3代表氫、低碳烷基、羧基、低碳烷氧基-羰基、低碳烷 基-胺甲醯基、羥基-低竣烷基、二-低碳烷基-胺基甲 基、嗎淋代藏基或4 ·( 4 -氟-节醯基)-喊淀 1 -基幾基, R 4代表氫、低碳烷基、羥基、羥基-低碳烷基、胺基-低 碳烷基、低碳烷基胺基-低碳烷基、二-低碳烷胺基-低 碳燒基、不飽和或經經基取代的低碳伸燒基胺基·低破 烷基、低碳烷氧基、低碳烷醯氧基、胺基-低碳烷氧 基、低碳燒基胺基-低碳燒氧基、二-低瑗烷胺基-低碳 坑氧基、自大Si亞胺-低碳燒氧基、不飽和或經幾基或經 2 -氧-咪唑烷-1 ·基取代的低碳伸烷胺基-低碳烷氧基、 羧基、酯化的或醯胺化的羧基、羧基-低碳烷氧基或酯 化的羧基-低碳烷氧基, X 代表視情況經鹵基取代的低碳伸烯基或伸炔基,其經 由附近的不飽和碳原子或偶氮N = N -)基鍵結,而 R 3代表芳族或雜芳族,其爲未經取代或被一或多個取代 基所取代’其取代基選自低旋燒基、齒基、鹵基-低緩 烷基、鹵基-低碳烷氧基、低碳鏈烯基、低碳鏈炔基、 未經取代或經低碳烷基_、低碳烷氧基-、卣基-和/或 一氣甲基-取代的笨基、未經取代或經低碳烷基·、低 蛟烷氧基·、齒基-和/或三氟甲基-取代的笨基-低碳 块基 ♦基、.¾基-低碳烷基、低碳燒驗氧基_低碳燒 低%L '丨7〇氧基、低唆、丨布氧基、低碳伸燒二氧基、低 本紙張尺度剌胁(2107^7 (讀先閱讀背面之注意事項再填寫本頁) •裝- 、1Τ 4 544448 A7 B7 發明説明(5 ) 唆燒醯氧基、胺基-、低碳烷胺基-、低碳烷醯胺基-或 N -低緩烷基-n -低碳烷基-N -低碳烷醯胺基-低碳烷氧 基、未經取代或經低後坑基-、低碳烷氧基-、鹵基-和 /或三氟甲基-取代的苯氧基、未經取代或經低碳烷基 -、低後烷氧基-、卣基-和/或三氟甲基-取代的苯基_ 低碳燒氧基、醯基、羧基、酯化的羧基、醯胺化的複 基、氰基、羧基-低碳烷基胺基、酯化的羧基-低碳烷 胺基、醯胺化的羧基-低碳烷胺基、亞磷酸基-低碳虎 胺基、酯化的亞磷酸基-低碳烷胺基、硝基、胺基、低 碳烷胺基、二-低碳烷胺基、醯胺基、N -醯基_ N ·低峻 坑胺基、苯胺基、苯基-低碳烷胺基、環烷基-低碳燒 胺基或雜環芳基-低碳烷胺基,其中的每一者未經取代 或經低碳燒基-低碳烷氧基-、卣基-和/或三氟甲基_ 取代, 慣用的親光性配位子和慣用的射線活性標記物(含括它們的 N -氧化物)及它們於藥用上可被接受的鹽類。 經濟部中央標率局員工消費合作社印繁 (請先閱讀背面之注意事項再填寫本頁) 式I化合物有鹼性基圑能夠形成酸加成鹽,式丨化合物有 酸性基圑能夠形成鹼加成鹽。式I化合物有鹼係基圑及至少 一個酸性基圑,可形成内鹽。 亦含括全鹽或部分鹽,即,式I的每莫耳酸有1,2或 3 (以2爲佳)當量鹼之鹽類,或式I的每莫耳鹼有1 , 2或 3(以1爲佳)當量酸之鹽類。 就分離或純化的目的’也能夠使用樂用上無法接受的鹽 類。僅藥用上可接受、無毒鹽類可用於治療,因此以它們 -B - 本紙張尺度適用中國國家標準(CNS ) A4規格(210X 297公釐) 544448 A7 B7 經满部中央標準局員工消費合作社印繁 五、發明説明(6 ) 爲佳。 此描述中的鹵素是指氟、氯、溴或碘。 X代表鏈晞基時,以順式構形爲佳。 較佳的式I化合物中, X 代表經由附近的不飽和碳原子鍵接視情況被鹵基取 代的(C 2 _ 4 )伸鏈垸基, R 1是氫,(C〗-4)烷基、(C丨_ 4)燒氧基、#圼基(C丨· 4 )烷 基、氰基、乙炔基、羧基、(C 1 _ 4 )烷氧基羰基、二 (c ] _4 )燒基胺基、(c】_ 6 )烷基胺基羰基、三氟甲基苯 基胺基羰基, R 2是氫,輕基、(C丨_ 4 )燒基、經基(C丨_ 4 )垸基、(C丨_ 4 ) 坑氧基、致基、(C 2 _ 5 )燒醯氧基、(C丨_ 4 )燒氧基馥 基、二(C ] -4 )梡基胺基(C 1 ·4)烷醯基、二(C ! ·4 )烷基 胺基甲基、4 - ( 4 -氟苄Sfe基)·喊啶-1 ·基-幾基、4 -第三 丁氧基談基喊嗉-基-幾基、· 4 - ( 4 -疊氮基-2 -幾基节 基)-喊唤-1-基-敌基或4-(4 -疊氮基-2-幾基-3-破-苄醯基)-哌嗉-1 -基羧基, R3是氫、烷基、羧基、(C〗_4)烷氧基羰基、(Cm) 烷基胺甲醯基、羥基(C】_4 )烷基、二(C i _4)烷基胺基 甲基、嗎啉代羰基或4 - ( 4 ·氟苄醯)-哌啶-1 -基羧基, R4是氫、羥基、(C】_4)烷氧基、(C2_5)烷醯氧基、(Ci_4) 士元氧基觀基、胺基(C丨_ 4 ) fe氣基、二(C 1 · 4 )燒基胺基 (C】_4)烷氧基、二(CVO烷基胺基(CV4)烷基、羧基 (C,_4)烷基羰基、(C! _4)烷氧基羰基(Ci-4)烷氧基、 —_____ - 9-_____ 本紙張尺度適用中國國家標準(CNS ) A4規格(210X 297公釐) (請先閱讀背面之注意事項再填寫本頁) 裝·
、1T 4 544448 A7 — ___B7 五、發明説明(7 ) 羥基(C】·4)烷基、二(Cl_4)烷基胺基((:14)烷氧基、 間-羥基-對-疊氮基苯基羰基胺基(c i _ 4)烷氧基,而 R 5是下列基團
Η 其中, 經满部中决標率局員工消費合作社印繁 (讀先閲讀背面之注意事項再填寫本頁) R a和R b分別是氫、羥基、齒素、硝基、氰基、羧基、(C } _ 4 ) 基、(C 1 _ 4 )烷氧基、羥基(C i _ 4 )烷基、(C丨· 4 )燒 氧基羰基·、( C 2 · 7 )烷醯基、(C 2 _ 5 )烷醯氧基、(C 2 _ 5 ) 坑酿氧基(C ] _4) fe基、三氟甲基、三氟甲氧基、三曱 基甲碎坑基乙炔基、(c 2 _ 5 )鏈炔基、胺基、疊氮基、 胺基(C丨_ 4 )烷氧基、(C 2 _ 5)烷醯基胺基(c丨· 4)烷氧 基、(Ci·4)烷基胺基(c】-4)烷氧基、二烷基胺 基(C丨· 4 )烷氧基、(C丨_ 4 )烷基胺基、二(C 1 _ 4 )烷基胺 基、一鹵节基胺基、嘍嗯基甲基胺基、嘧嗯基羰基胺 基、二氟甲基苯基胺基羰基、四吐基、(C 2 _ 5 )丨完醯基 胺基、芊基羰基胺基、(C 1 _ 4)烷基胺基羰基胺基、 (C 1 _ 4 )坑氧基談基-胺基幾基胺基或(C i _ 4 )、院基績酿 基, ^__-10- _ 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) M4448 A7 B7 五 、發明説明(8
R R ^ C是氫、氟、氯、溴、超基、/广 一 I (Ch4)烷基 氧基、(C〗_4)烷氧基或氰其 公’而
Rd是氫、鹵素或(Cm)烷基。 更佳的式I化合物是X如前兩批^ D V义義,但R基團如下者. R】是氫,(Ch)烷基、(Cl计 有. 烷虱基、氰基、乙块 二(C丨_4)烷基胺基, 基或 是氫,羥基、羧基、(C〗、^ 】-4)烷虱基羰基、二(c 基胺基甲基、4·(4·氟-;_ A _4)" ^ % -哌哫-1 -基-羧基、4 第三丁氧基羰基哌嗪-1- 卷K基、4-(4-疊氮基-2_羥 基芊醯基)-喊嗪-1 -基-幾其七 α ^ 工 夂%或4 - ( 4 - ®亂基-2 -幾基-3 _ 碘-苄醯基)-哌嗉-1 _基幾基, 如前面所定義者, 疋氫、嫂基、竣基、(C2·5)烷醯氧基、(Ci 4)烷氧基 恢基、fe:基(CW4) 氧基、二(Ci _4)烷基胺基(Ci4) 烷氧基、二((:丨_4)烷基胺基(C1_4)烷基或羥基(C1_4) 燒基,而 R 5是下列基圑 (請先閲讀背面之注意事項再填寫本頁) .裝. -訂· 經滴部中央標準局員工消費合作社印繁 R, 或 R, 其中 R a和R b分別是氫、卣素、硝基、氰基、(C丨_ 4)嫁基、(〔 -11 - 本紙張尺度適用中國國家標準(CNS ) A4規格(210X 297公釐) 544448 A7 B7 五、發明説明(9 工氟甲基、三氟甲氧基或(C2_5)鏈炔基, 經濟部中央標牟局員工消費合作社印繁 4 )貌氧基 而 R c和R d如前面所定義者。 本發明之物劑包括,如:下文中的例子所述的化合物。 本發明之物劑於治療前述失調上之用途可有下列標準試 驗件到證賞: 以腹膜内或P . 〇 ·方式施用約1 〇至10〇毫克/公斤藥量而 預先處理1 5分鐘至8小時,本發明之物劑在電擊誘發的抽 筋模式中顯現抗抽筋活性[請參考E A. Swinyar(j, j. Pham· Assoc. Scient. Ed·,丛,201 (1949 )和 J. Pharmacol. Exptl. Thei.ap·逝,3 1 9 (1952 )]。 以Ρ·〇.方式施闬約4至40毫克/公斤劑量,本發明之物 劑在Freund完全輔助劑(F C a )誘發的痛覺過敏中顯現逆轉 十同況[請參考 j· Donnerei·等人,Neuroscience 41, 693-698 ( 1992 )和 C.J· Woolf, Neuroscience 62_, 327-33 1 (1994 )。 就所有的前述指示,適當劑量當然視,如:所用的化合 物、施用對象、施用方式、及欲治療疾病的木質和嚴重程 度而改文°但是,通常,每日施用量約〇 5至約1 〇〇毫克 /公斤動物體重,可以得到令人滿意的結果。用於大型哺 乳:物(如:人類)時·容易每日分高至四次施用的化:物 或是持續釋出的化合物之每日劑量約5至15 至約1〇〇0毫克爲佳。 毛兄、、勺 前述指示的較佳的化合物包括(3 ·丨2 _ [ 2 _順_㈠5 _二氯苯 基)乙晞基]-6-甲基-吡啶_2_基氧基卜丙基)_二甲基胺 -12- 本紙張尺度適用中國國家標準(CNS ) A4規格(2H)>< 297公釐 I !-1 ...... - - - - - - I- - ---- ---- 0 1讀先閱讀背面之注意事項#填寫本貢) 訂 Φ 544448 經濟部中央標率局員工消費合作社印製 A7 B7 五、發明説明(10 ) (A)、2 -甲基-6 -笨乙烯基吡咬(β)、2七_氣-苯基乙块 基)-6·甲基“比咬(C)和2-(仁乙氧基-三氟甲基-苯基乙決 基)-6-甲基“比咬(D)。例如,已經在前述電擊誘發的抽筋 模^中得知化合物八和8有抗抽筋活性,心。分別是3〇和 3 5耄克/公斤腹膜内施用(前處理時間分別是4小時和1 5分 鐘),前述FC A誘發的痛覺過敏模式中,化合物〔和〇顯示 痛覺過敏逆轉情況,ED”分別是4 2和19毫克/公斤p 〇 施用(後處理時間:3小時)。 如前述者,本發明之物劑包括新穎的芳基鏈烯基_、2_ 雜方基鏈%基_、2 -芳基鏈炔基·、2 _雜芳基鏈炔基·、2 _芳 基偶氮_和2-雜芳基偶氮_吡啶及其鹽類,下文中稱爲”本發 明之化合物”。 本發明I化合物包拾前面所定義的式丨化合物,及它們的 鹽類,其中,X和L至R5如前面之定義,但當R3是氫時, a)在其R 1、R 2和R4是氫的式I化合物中,當X代表乙烯 基時,R5不是笨基、一鹵代笨基、2,4-和3,仁二氯苯 基、3 -和4-三氟曱基苯基、甲基苯基、3,4_和2,5_二 甲基苯基、4·異丙基苯基、3,5_二·第三丁基苯基、甲 氧基苯基、3,4-二甲氧基苯基、2,4,5-和3,4,5-三甲 氧基笨基、羥基笨基、3,5 -二羥基笨基、4 -羥基-3,5-—甲基私基、3-¾基-4 -曱氧基·和4-經基》3 -甲氧基-苯基、4_羥基_(3_甲基_5_第三丁基,2_和4•乙醯基胺 基笨基、3. 5-二異丙基·和3,5-二-第三丁基)苯基、4_ 罗艾基和4 -乙氧基|基苯基、4 -氰基笨基、3 -甲氧基藏 __ 一 - 13- 本紙張尺度適用中國國家標準(CNS ) A4規格(210X 297 ^¾ ) '~' ' (讀先閱讀背面之注意事項再填寫本頁) 裝·
、1T 544448 A7 B7 五、發明説明(11 經濟部中央標準局員工消費合作社印製 基苯基、j -幾基_ 5 -甲氧基_笨基、2 - p比咬基、5 _氯_ 2 _ 吡啶基和6-甲基_2_吡啶基:或者,當X代表接在r5的 2-位置上的ι,2_伸丙基時,Rs不是苯基、4_甲基苯 基、4 -甲氧基苯基、4 -溴苯基和2 -及4 -氯苯基:或 者,當X代表接在I的b位置上的1,2_伸丙基時, 不疋苯基、2 -和4 -氯笨基和3-甲氧基笨基;或者,當 x代表接在R 5的2 -位置上的2,3 _伸丁 _ 2 -基或1,2 _伸丁 1基時,R 5不是4 -甲氧基苯基:或者當χ代表接在 尺5的3_位置上的2,3-伸戊基時,R5不是4 -甲氧基 本基和4_異丙基苯基··或者,當X代表3,4-伸己-3-基 時’ I不是笨基、4-甲基苯基、甲氧基苯基和4-羥基 笨基: b )其R 1是甲基而R2和I是氫的式1化合物,當χ是伸乙 基時’ L不是苯基、3 -曱基苯基、2-甲氧基苯基、2- 氯苯基、4-氰基笨基、2 _吡啶和卜甲基_2_吡啶基: c )其R 1和R 2是氫而R4是複基的式I化合物,當X是伸乙 基時,R 5不是苯基、3 _甲基苯基、2 _甲氧基苯基和4 _ 溴苯基: d)其Rl和是氫而R4是甲基的式I化合物,當X是伸乙 基時,R 5不是苯基、3 -甲氧基-、4 -甲氧基-和3,4 -二 曱氧基笨基、2 -氯-和2,4 -二氯苯基及6 -甲基-吡啶- 2-基’或者:當X是接在R 5的2 ·位置上的〗,2 -伸丙-1 _基 時,R 5不是苯基: e )其R 1和汉2是氫而R4是2 _二甲基胺基乙氧基羰基或3 -二 -14- 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐 —ΊΤ (讀先閱讀背面之注意事項再填寫本頁) -裝· 、1" 經满部中央標準局員工消費合作社印聚 544448 kl ____ B7 五、發明説明(12 ) 甲基胺基丙氧基羰基的式I化合物,當X是伸乙基時, R5不是4-甲氧基笨基: f) 其R 1和R 2是氫而R 4是2 ·二甲氧基乙氧基的式I化合 物,當X是伸乙基時,R 5不是苯基、4 -曱基笨基和4 · 甲氧基羰基苯基: g) 其Ri和是氫且R4是輕基或乙氧基鍰基,或者,其 Ri和R2是氫且1^是輕基,或者,Ri是甲基且以2是氫 且R4是甲氧基,或者,Ri是丁-1-烯基且R2是氫且r4 是氫,或者,R!是氫且R4是2 -二曱基乙氧基且前述的 每個X都是伸乙基時,R 5不是苯基: 但當R 3是氫,X是乙块基時: a ’)當R丨、R 2和R4是氫時,r 5不是苯基、2 -和4 -硝基苯 基、4 -胺基苯基、4 -氣苯基、4 -甲基笨基、4 -甲氧基 笨基、4 -乙氧基羰基笨基、5 -曱醯基—2 -甲氧基-苯 基、5 -竣基-2 -甲基-苯基和U比咬基: b ’)R 2和R 4是氫的式1化合物中,R】是甲基時,R $不是苯 基、3 -甲基苯基、6 -甲基吡啶-2-基和2 -甲氧基苯基: R !是溴時,R 5不是6 -溴吡啶-2 -基:R 1是己氧基時, R5不是6 -己氧基p比η定-2-基: c ’)其R !和R 4是氫的式I化合物中,r 2是甲基時,r 5不是 苯基、4 -胺基苯基和4 -丙基苯基:R2是乙基時,尺5不 是苯基、4 -氰基笨基和4 -戊基苯基:1^2是丁基時,r5 不是3 -氰基-4 -乙氧基-苯基和3 -溴-4 -甲氧基-苯基; R2是戊基時’ R5不是4 -甲氧基苯基和4 -丁氧基苯基: t____-15- __ 本紙張尺度適用中國國家標率(CNS ) A4規格(210X297公釐) —ΊΤ (讀先閱讀背面之注意事項再填寫本頁) -裝· 544448 A7 五、發明説明(13 ) R2是羧基時,R5不是4 -第三丁基苯基、3_第三丁基-4 -爽基木基、4 -第三丁基- 3-¾基-笨基和4 -己氧基苯 基:R2是曱氧基羰基或甲基胺基曱醯基時,r5不是苯 基:R2是乙氧基羰基時,R4不是3 -第三丁基苯基、3 _ 第三丁基-4-羥基苯基和4-(4-甲基戊基)苯基:r2是 2 -甲基丁氧基羰基時,R 5不是4 -戊氧基苯基: d ’)其R !和R 2是氫的式I化合物中,當r 4是超基、甲基、 乙基、羧基、甲氧基羰基或胺基甲醯基時,R 5不是苯 基、 本發明之較佳的化合是前述的本發明之物劑。 本發明之化合物可藉與合成已知的式1化合物之方法類似 的方式製得。 因此,本發明之式I化合物之製法包含 a)使式II化合物 (請先閱讀背面之注意事項再填寫本買) 裝- 、1'
經滴部中央標準局員工消費合作社印繁
與式Y2化合物一Km)反應,其中,Υι和γ2之一代表低 碳烷醯基,另一者代表低碳烷基或三芳基 phosphoranylidene甲基,或者,YdpY2之一代表具反應性 的酯化羥基,另一者代表基團γ 3 - X -,其中,丫3是氣或金 屬基圑,R】、R 2、R 3、R 4和R 5如前面所定義者,R -16 - 本紙張尺度適用中國國家標準(CNS ) Α4規格(210X 297公釐)^-- 544448 A7 B7 五、 發明説明(14 尺2、R3、R4官能基及R」官能取代基可以暫時受到保護 或者 b )由式IV化合物消去Η - Y 4 、'广 (IV), 經滴部中央標率局員工消費合作社印繁 其中’ Υ4代表離電子基,Rl、R2、R3、R4、乂和^如前 面之定義,官能基L、r2、h和^及化5官能取代基可以 暫時受到保護,移除任何的暫時保護基,及,必要時,將 由前面所定義的方法可得到的式丨化合物轉化成不同的式J 化合物,將可能得到的異構物混合物解析成單獨的異構物 和/或將前述定義方法中可得到之有至少一個成鹽基團的 式I化合物轉化成鹽,或者,將可由前述定義法得到的鹽轉 化成相關的自由化合物或轉化成不同鹽。 低碳烷醯基Y2或更佳的Υι基團時,如:Ci-C3烷醯基 (如:甲醯基、乙醯基或丙醯基,特別是甲醯基)。低碳烷 基丫!或更佳的Y2是,如:Ci-(:3烷基(如:甲基、乙基或 丙基,特别疋甲基)。三芳基ph〇sph〇ranyHdene γ 2或更佳 的 Yl 疋,如·二苯基 ph〇Sph〇ranylidene 甲基。 Y 1和Y 2 I 一是具反應性的酯化羥基且另一者是式γ 3 _ X 基團(其中,Υ3代表氫)時,縮合反應以根據Heck偶合法實 犯馬佳,例如:實施時,有銅或銅觸媒存在,或有貴金屬 -17 本紙張尺度適用中國國家標準(CNS ) A4規格(21 Ο χ 297公釐) (諳先閱讀背面之注意事項再填寫本頁) -裝· 、1Τ 8 44 44 五、 發明説明( B7 15 t 7 =(-如/三級啤的鈀或pd(n)鹽,如:醋酸1已)存 ’ 一有—广基膦存在’或有雙-三苯基膦-二氯化鈀存在 \二m基胺(如:三曱胺)存在爲佳),有利的情況 疋Cu⑴1存在於極性有機溶劑(如:N,N_二(低碳烷基) 反基酸驢胺(如:二甲替甲醯胺)、二(低碳虎基)亞職(如· t甲亞颯)或〕惡垸)中於約15τ至約12(rc(以於海點爲佳) 實施爲佳。 γ 1和Y 2之一代表具反應性的酯化輕基,另一者代表式 Y 3 - X基圑(其中’ γ3代表金屬基團,如:圏帶鎂基))時, 此反應以根據Gngnard法實施爲佳,其中,金屬中間體以 於原處形成爲佳。 Y 1和Y 2 (—代表低碳烷醯基,另一者代表低碳烷基時, 式Π和III化合物的分子内縮合反應以根據Shaw和 Wangstaff法或其許多修飾法之一進行爲佳。 Y!和Y2之一代表低碳烷醯基,另一者代表三芳基 phosphoranylidene甲基時,此縮合反應以根據習知的 Wittig烯烴構築法實施爲佳,以由相關的三芳基膦鹵化物 於當場形成phosphoranylidene構份爲佳(如:使後者與金屬 鹼(如:驗金屬氫化物,如:氫化鈉)反應,或者使後者與 金屬有機臉(如:低碳燒基金屬化合物,如:丁基鍾)反 應,或者使後者與鹼金屬烷醇鹽(如:三級丁氧化鉀)反 應),此反應以於惰性有機溶劑(如:苯或甲苯)中於約-1 0 °C至約3 9 X:(以先於〇 °C至1 0 °C ),之後於常溫爲佳)進行爲 佳。 -18 本紙張^適用中國國家CNS ) A4規格(210X 297公釐) (讀先閱讀背面之注意事項再填寫本頁) •裝·
、1T 經滴部中央標率局員工消費合作社印絮 544448 ΚΊ 經濟部中央標率局員工消費合作社印繁 五、發明説明(16 ) 離電子基Y4是,如:酯化的禮基(如:被有機酸g旨化的 羥基(如:低碳烷醯氧基)或被無機酸酯化的羥基(如:_基 或三級胺基(如:三低碳烷基胺基(如:三甲胺基))、低碳 氮雜伸坑基胺基、低碳氧伸烷基胺基或低碳三伸燒基胺基 (如:吡咯基、吡啶基、嗎啉代或硫代嗎啉代))或相關的四 級銨基。 官能基以這樣的保護基保護,保護基本身及它們的移除 反應述於,如:標準著作中。 由式IV化合物除去Η- Y4可藉慣用的方式進行。因此, 水或低碳烷基酸可藉共沸蒸餾法(如:在甲苯中,以於溫和 酸性條件下爲佳)去除。鹵化氫可於鹼性條件下去除,如: 與鹼金屬烷醇鹽反應(以於相關低碳烷醇作爲溶劑或輔助溶 劑時爲佳)或者藉由在三級胺(如:三-低碳烷基胺)存在時 加熱。 前述反應的起始物已爲習知,根據製備已知起始物類似 的方法可製得新的起始物。 根據此方法可得的式丨化合物可以慣用的方法轉化成不同 的式I化合物,慣用的方法如:將自由的羧基加以酯化或醯 胺化’可以將酯化或醯胺化的羧基轉化成自由的幾基,可 將酷化的羧基轉化成未經取代或經取代的胺基甲醯基,可 將自由的胺基加以醯化或烷基化,可將自由的羥基加以_ 化。 -敌 同樣地,可藉慣用的方法(如:與有機過氧酸反應)將式I 化合物加以氧化’得到相關之ρ比淀-Ν _氧化物衍生物。 __— _ 19- 本紙張尺度適用中家標隼(CNS ) Μ規格(21〇χ—Μ7公襲) ' ' --- ijm. (請先閱讀背面之注意事項再填寫本頁) •裝- 、-口 Φ 544448 A7 B7 五、 發明説明( 17 經滴部中央標準局員工消費合作社印f 可以目前已知的方式將式Ϊ化合物的鹽類轉化成自由化合 物,如:以驗或酸處理。 所得鹽可藉目前已知的方法轉化成不同鹽類。 式I化合物(包括其鹽類)可以水合物形式得到,或者可包 括結晶用的溶劑。 因爲自由形式的新穎化合物與其鹽類形式的新穎化合物 <間的關係,下文及前文中所提到的自由化合物及其鹽類 係包括自由化合物及其相關鹽類。 式I化合物中,各個對掌中心的構形可選擇性地反轉。例 如,帶有親核取代基(如:胺基或羥基)之不對稱碳原子的 構形可因爲第二順位親核取代作用而反轉,視情況地在鍵 結的親核取代基轉化成適當的離核離去基並與引入原取代 基的物劑反應之後而反轉,或者,有羥基的碳原子構形可 以因爲氧化反應或還原反應而反轉,此類似於Europe⑽ Patent Application ΕΡ-Α-0 236 734。 本發明亦係關於包含式丨化合物的藥用組合物。 本發明之藥用上可接受的化合物可用於,如:製備包本 藥效量活性成物之藥用組合物亦包含大量無機或有機、^ 態或液態藥用上可接受的載劑之藥用組合物。 根據本發明之藥用組合物可是經腸(如:鼻用、直腸用戈 口服)或非經腸(如:肌肉内或靜脈内)組合物,施用於溫: 動物(人類和動物),包含有效量藥用活性成份或另包= 量藥用可接受載體。活性成份的劑量視溫血動物種類二 重、年齡和個別狀況、單獨的藥物動力數據、治療的疾= 20- 本紙張尺度適用中國國家標準(CNS ) A4規格(210X297公釐) (請先閱讀背面之注意事項再填寫本頁) -裝-
、1T Φ 544448 A7 B7 五、發明説明(18) 及施用模式而定。 此藥用組合物包含約1 %至約95 %(以約20%至约90%爲 佳)的活性成份。根據本發明的藥用組合物可以是,如,以 單包裝形式,如:安瓶、小瓶、栓劑、糖衣藥丸、錠劑或 膠囊形式。 本發明之藥用組合物以目前已知的方式製備,如:利用 慣用的溶解、凍乾、混合、造粒或裹糖衣法。 藥劑施用在溫血動物(如:體重約7 0公斤的人類),治療 與谷胺酸訊息傳遞不規則有關的失調之特別有效的劑量是 約3毫克至約3克,以約1 0毫克至約1克爲佳,如:約2 0亳 克至500毫克/人/天,分1至4次施用,每次可施用相同 量。通常,孩童劑量約成人半量。每個個體所須施藥量可 由測定血清中的活性成份濃度來測定並調整至最適量。 下列不具限制性的實例用以説明本發明:實施例的溫度 單位是°C,壓力單位是毫巴。 實例1 3 - [ 2二(6 -甲基吡啶-2 -基)-乙烯基1苯甲腈 經漓部中央標準局員工消費合作社印^ (請先閱讀背面之注意事項再填寫本頁} 2,6 -二甲基吡啶(4.2毫升,36.28毫莫耳)、3 -氰基苯甲 醛(4.59克,37.74毫莫耳)在醋酸酐(6.85毫升)中之溶液迴 餾加熱1 6小時。然後,此醋酸酐在眞空中蒸發,殘渣以管 柱層析術(矽膠400克)純化。管柱先以甲苯(400毫升)沖 提,然後以甲笨/乙酸乙酯9 5 : 5沖提。合併含有所欲化 合物的鶴份’在眞空中蒸發。固態渣質由二氯甲烷/己燒 再結晶,分離出3.1 8克白色固體(熔點:9 1 - 9 2 °C )。 _______ _-21 -_ 本紙張尺度適用中國國家標準(CNS ) A4規格(210X 297公釐) 544448 A7 B7 五、發明説明( 19 -—-------- 經漓部中央標率局員工消費合作社印製 實例2 比啶-2 ·基)-·乙瘦甲腈 2,6-二甲&比啶(5.8毫升,50毫莫耳)、2_氰基苯甲酸 (6.81克,52¾莫耳)在醋酸酐(95毫升)中之溶液迴餾加熱 16小時。然後,此醋酸酐在眞空中蒸發,殘渣以管柱層析 術(矽膠400克)純化。管柱先以甲苯(4〇〇毫升)沖提,然後 以甲苯/乙酸乙酯95 : 5沖提。合併含有所欲化合物的餾 份,在眞空中蒸發。固態渣質由二氯甲烷/二異丙醚再結 晶’分離出白色晶體(溶點:1 i 3 - 1 i )。 實例3 6 - [ 2 -吡淀-4 -基)-乙烯某1毗诠 2,6 - —甲基ρ比淀(5 · 8毫升,5 0毫莫耳)、ρ比淀-4 -甲酸 (4.9毫升’ 5 2愛莫耳)在醋酸纤(9 · 5毫升)中之溶液迴|留加 熱1 6小時。然後,此醋酸酐在眞空中蒸發,殘渣以管柱層 析術(珍膠900克)純化。> 管柱先以甲苯/丙酮4 : 1 ( 5升)沖 提,然後以甲苯/丙酮3 : 1 ( 5升)沖提,最後以甲苯/丙 酮3 : 1 ( 5升)沖提。合併含有所欲化合物的餾份,在眞空 中蒸發。固態渣質由二氯甲烷/二異丙醚再結晶,分離出 0.965克白色固體(熔點:7 2 - 7 3 X:)。 實例4 2 -甲基-6 - f 2 -吡啶-3 -基)-乙烯基1吡啶 2,6 -二甲基π比啶(5.8毫升,5 0毫莫耳)、吡啶-3 -曱駿 (4.9毫升,5 2毫莫耳)在醋酸酐(9.5毫升)中之溶液迴餾力口 熱1 0小時。然後,此醋酸奸在眞空中蒸發,殘;查以管柱層 -22 - 本紙張尺度適用中國國家標準(CNS ) A4規格(210X 297公釐) ----- (讀先閱讀背面之注意事項再填寫本頁) ;裝· 544448 經满部中央標準局員工消費合作社印$ί A7 B7 五、發明说明(2Q ) 析術(矽膠900克)純化。管柱先以甲苯/两酮9 : 1 ( 7升)沖 提,然後以甲苯/丙酮4 : 1 ( 5升)沖提,最後以甲苯/丙 酮2 : 1 ( 5升)沖提。合併含有所欲化合物的餾份,在眞空 中蒸發。固態渣質由二氯甲烷/二異丙醚再結晶,得到 4 · 2 8克無色油,其於6 - 8 °C靜置而固化。 Am 2 _ [ 溴苯暴)卜ό _甲基_p比淀 1.2克(2.8毫莫耳)2-[1,2-二溴-2(3-溴苯基)-乙基]-6- 甲基-吡啶溶解於1 0毫升乙醇中。添加〇9克(16 j毫莫耳) 氫氧化鉀(粉末)’所得懸洋液迴餘加熱4小時。然後將懸浮 液冷卻至室溫,倒入1 〇〇毫升鹽水中,以第三丁基甲基醚 萃取兩次(每次3 0毫升)。合併的有機相以3 〇毫升鹽水清洗 兩次,以硫酸鈉乾燥,過滤並在眞空中蒸發。得到〇 720克 標題化合物,其爲無色油,靜置之後結晶:熔點:60-61 °C。 起始物得自: a) 2 -『2 - ( 3 -溴苯基)-乙烯基1 - 6 -甲 24毫升(200毫莫耳)2,6-二甲基吡啶和25.6毫升(2〇7毫 莫耳)3-溴苯甲酸於38毫升醋酸奸中之溶液迴餾加熱7.5小 時,醋酸酐在眞空中蒸發,殘渣溶解於5〇〇毫升4 N鹽酸 中,以己烷萃取兩次(每次200毫升)。然後,水相以第三丁 基甲基醚萃取四次(每次300毫升)。合併的有機相以 NaHC03飽和水溶液清洗兩次(每次3〇〇亳升),然後以3〇〇 毫升鹽水清洗一次,以歸:酸鈉乾燥,過遽並於眞空中乾 -23- 本紙張尺度適用中國國家標準(CNS ) Α4規格(210X 297公釐) ------ij· 装-- (讀先閱讀背面之注意事項再填寫本頁)
、1T -Φ 544448 經滴部中央標準局員工消費合作社印$1 A7 B7 五、發明説明(21) 燥’仔到4.2兄標題化合物’其爲溶點5 8 _ 5 9的無色晶 體。 b) 2-「1,_^_1_^溴-2-(3-溴笨基卜乙基1_6-甲基-吡啶 1克(3.6毫莫耳)2 - ( 3 -溴-苯基乙炔基)_ 6 -甲基-峨淀溶解 於5毫升四氣化碳中,溶液加熱至5 5 -6 0 °C。逐滴添加0.23 毫升(4 · 4毫莫耳)溴的〗毫升四氯化碳溶液。此反應混合物 維持於5 5 - 6 (TC達3 0分鐘,之後冷卻至室溫。以過濾法收 集所得沉澱物並於眞空中乾燥。分離出1.3克標題化合物, 其爲黃色晶體,熔點丨64 - 1 66 °C。 實例6 3 - [ 2 - ((3 ·甲基吡啶-2 -基)乙炔基]苯曱腈 1克(8.54耄莫耳)2 -乙炔基-6 _曱基-吡啶(以類似於d.e.
Ames 等人,Synthesis,364-5 (1981 )製得)、2.3 克(12.8 毫莫 耳)3 -溴-苯甲腈、0.47克(0.7毫莫耳)雙_(三苯基膦)·氯化 飽(II )、8 0毫克(0.41毫莫耳)碘化銅和丨.53毫升(丨5毫莫耳) 三乙胺於1 0毫升二甲替甲醯胺中之混合物於9 〇 攪掉3小 時。將此反應混合物冷卻至室溫’倒入水中,以二氯甲嫁 萃取。有機層以硫酸鈉乾燥,過濾,蒸發,渣質以層析法 在發膠上純化,以己燒/乙酸乙酯(4 : 1}作爲沖提液。所 得產物由己烷結晶,得到0.53克(28.4%)標題化合物,其 爲棕色晶體,熔點1 20 - 3 °C。 實例7 以類似於實例1(其中的X是伸烷基)或實例5(其中的乂是 伸晞基)的方式,製得下列式I化合物: _______-24-_ 本紙張尺用中國國家標率(CNS ) A4規格(210X 297公釐) — .一 -—- ~IT (讀先閱讀背面之注意事項再填寫本頁) 544448 A7 B7 五、發明説明() 經滴部中央標準局員工消費合作社印絮 式I化合物 熔點(°C) 2-苯乙烯基^比啶-3-醇 249-252 2-甲基-6-[2-(3-硝基-苯基)-乙烯基]•吡啶 100-101 2-[2-(2-氯-苯基)-乙烯基]-吡啶 無色油 2-甲基-6-苯乙烯基-口比啶 40-42 醋酸6-[2-(2-氯-苯基)乙晞基]-吡啶-3_基酯 75-77 6-[2-(2-氯-苯基)乙烯基]-吡啶-3-醇 168-171 醋酸2_[2-(2-氯-苯基)乙烯基]-吡啶-3-基酯 99-102 2-[2-(2-氯-苯基)乙烯基]-吡啶-3-基 232-234 6-甲基-2-苯乙烯基4比啶-3-醇 261分解 醋酸2-[2-(2-氯-苯基)乙晞基]-6-甲基-吡啶-3-基酯 92-94 2-[2-(2-氯-苯基)-乙晞基]-6-甲基-口比啶-3-基 232-234 (Ζ)·6-甲基-2-笨乙烯基-外1:啶-3-醇 145-148 2-[2-(2·氯-苯基)-乙烯基]-6-曱基-口比啶 51-52 2-[2-(2-氣-麥基)-乙缔基]-叶匕口足 69-70 2-[2-(2_硝基-冬基)-乙細基]-’比呢 97-99 醋酸2-[2-(4-氯-苯基)-乙烯基]-6-甲基-吡啶-3-基酯 102-103 醋酸6-[2-(4-氯·苯基)-乙烯基]-2-曱基-吡啶-3-基酯 130-131 2-[2-(4-氣-冬基)-乙細基]-6-甲基-ρ比咬3-酉竽 275-278 分解 6·[2-(4·氣-木基)-乙缔基]-2-甲基-p比咬-3-Sf· 265-270 分解 醋酸6-甲基-2-[2-(2-硝基-苯基)-乙烯基]-吡啶-3-基酯 139-140 6-曱基-2-[2-(2-硝基-笨基)-乙烯基]-吡啶-3-醇 190_195 分解 醋酸2-甲基-6-[2-(2-硝基-苯基)-乙晞基]-吡啶-3-基酯 99-100 2-曱基-6-[2·(2-硝基-苯基)-乙烯基]吡啶-3-醇 230-233 分解 醋酸2-[2-(3-氯-苯基)-乙烯基]-6-甲基-吡啶-3-基酯 97-99 --------裝-- (讀先閱讀背面之注意事項再填寫本頁) -25- 本紙張尺度適用中國國家標準(CNS ) A4規格(210X 297公釐) 544448 A7 B7 五、發明説明(25) 經滴部中央標準局貝Η消費合作社 {2-[2-(2-氯-苯基)-乙烯基]-6-甲基氧基卜醋酸乙酯 無色膠 3-[2-(6-甲基-吡啶-2-基)-乙蚪V、卜Ν-(3-三氟甲基-苯基)苯甲 醯胺:HC1鹽 249-25! 4-[2-(6-曱基-吡啶-2- V、)-乙綿基]-Ν-(3-三氟甲基-苯基)苯甲 醯胺 160-161 2-[2-(3-硝基H )-乙烯基]-吡啶 127-128 6-苯乙婦V、比咬-2-叛酸(3-氟甲基-苯基)-醯胺 128-129 2-(6- :V、乙岣基-口比啶-2-基)-丙-2-醇:HC1鹽 171-174 2」丨/ 4各(2-嘧吩-2-基-乙晞基)-吡啶;/HC1鹽 208-211 2^2-(3-氯-苯基f乙烯基]吡啶 / 51-53 2-[2-(3-氰基-苯基)-乙烯基]-吡啶 85-86 2-[2-(3-溴-苯基)-乙烯基]-6-甲基-吡啶 58-59 2-[2-(2>二甲氧基-苯基)-乙烯基]-6-甲基-吡啶 無色油 2-[2-(2,3-二氯-苯基)-乙晞基]-6-甲基-吡啶 67 - 68 2-[2-(3-氯·苯基)-1 -甲基-乙烯基]-吡啶 無色油 {2_[2-(2-氯-苯基)·乙烯基]-6-甲基-吡啶-3-基卜甲醇 87-90 2-甲基-6-[2-(3·三甲基矽烷基乙炔基-苯基)-乙烯基〗-吡啶 黃色油 2-[2-(3,4-二氟-苯基)-乙烯基]-6-甲基4匕啶 61^62 2-[2-(3-乙炔基-苯基)-乙烯基]各甲基-吡啶 黃色油 2-[2-(3,5-二氟苯基)-乙烯基]-6-甲基-吡啶 黃色油 2-[2-(3-氟-苯基)-乙烯基]-6-甲基-吡啶 黃色油 2-[2-(3-甲氧基-笨基)-乙缔基]-6-甲基-吡啶 黃色油 2-甲基-6-[2-(3-苯氧基-笨基)-乙烯基匕啶 黃色油 2-[2-(3-爷氧基-苯基)-乙晞基]-6-甲基匕淀 68-69 2-[2-(2,5-二氟-苯基)-乙晞基]-6-甲基-吡啶 44-45 {2-[2-(2-氯-苯基)-乙烯基]-6.·甲基-吡啶-3-基氧基)-醋酸 230^33 -28- (請先閱讀背面之注意事項再填寫本頁)
衣纸張尺度適用中國國家標準(CNS ) A4規格(210X 297公釐) 544448 A7 B7 五 發明説明(26) 經滴部中央標準局負工消費合作社印製 (3-丨2-[2-(3-氯·苯基)-乙烯基]-6-甲基-吡啶-3-基氧基}·丙基)-二甲胺 203-205 {6-丨2-(2-氯-苯基)-乙烯基]冬甲基-吡啶各基卜甲醇 131-133 2-(3-溴-苯基乙決基)-6-甲基-吡啶 61-63 2-甲基-6-丨2-[3-(3-三氟甲基-表氧基)-苯基]-乙缔基}-外匕淀 黃色油 2_[2-(3,5-二甲氧基-苯基)-乙烯基]各甲基-吡啶 43 - 45 2-[2-(3·氯-苯基)-乙烯基]:曱氧基各甲基-吡啶 52-53 醋酸4-澳-2-[2-(6_甲基-对1^定-2-基)-乙締基]-苯基酉旨 黃色油 醋酸3-[2-(6-甲基-吡啶-2-基)-乙晞基]苯基酯 黃色油 2-[2-(3,4-二氯-苯基)-乙烯基]-6-甲基-吡啶 73-75 4-溴-2-[2-(6-甲基4匕啶-2-基)-乙晞基]-酚 246-248 醋酸2-[2-(3,5-二氯-苯基)-乙烯基]-6-甲基-吡啶-3-基酯 156-158 醋酸6-[2-(3,5-二氣-苯基)-乙烯基]-2-甲基-吡啶-3-基酯 159-161 醋酸2·[2-(3,5·二氣-苯基)-乙烯基]-吡啶-3-基酯 154-156 2-甲基-6-(2-茬-1-基·乙晞基)-吡啶 黃色油 2-[2-(2,3-二氫-苯並[M]二喔星(dioxin)-6-基)·乙缔基]-6-甲基 -p比淀 99-101 2-甲基-6_(2-荅-2·基-乙烯基)-吡啶 97-99 2-甲基-6_(2-間-甲苯基-乙烯基)-吡啶 黃色油 2-{2-[3-(3,5·二氯-苯氧基)-苯基]-乙烯基卜6·甲基-吡啶 黃色膠 2-[2-(3-氯-笨基)-丙烯基]-6-甲基_吡啶 黃色油 2-[2-(2,3-二氯-苯並咬喃-5-基)-乙%基]-6-甲基-p比口定 88-90 2-[2-(4-氟-苯基)-乙晞基>6-甲基-吡啶 50-51 2-曱基-6-(2-鄰-甲苯基-乙烯基)-吡啶 黃色油 2-甲基各(2-對·甲苯基-乙烯基)-吡啶 85-86 2-甲基-6-(2-對-曱苯基-丙烯基)-吡啶 黃色油 (讀先閲讀背面之注意事項再填寫本頁) ΦΤ d- -29- 本紙張尺度適用中國國家標準(CNS ) A4規格(210X 297公釐) 544448 A7
7 B 五、發明説明(27 ) 經濟部中央標準局員工消費合作社印掣 3-[2-(6-甲基-吡啶-2-基)-乙烯基]笨胺 126-129 (2,3-二甲氧基-7-硝基-喹噁啉-5-基甲基)-丨3-[2-(6-甲基比啶-2-基)-乙烯基]-苯基卜胺 淡橘色泡沫 N- {3-[2_(6-甲基^比啶-2-基)-乙烯基]-苯基卜乙醯胺 147 N-丨3-[2-(6-甲基-说啶-2-基)-乙烯基]-苯基卜2-苯基-乙醯胺 156 2,2-二甲基-义{3-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯基}- 丙61胺 166-168 嘧吩-2-羧酸{3-[2-(6-甲基-吡啶-2-基)-乙晞基]_苯基卜醯胺 197分解 環己羧酸丨3-[2-(6-甲基-吡啶-2-基)-乙烯基]_苯基卜醯胺 215 1_(4_溴-苯基)-3_{3-[2-(6-甲基^比啶-2-基)-乙烯基]-苯基} •尿素 197 2一甲基-6-[2·(4-硝基-苯基)-乙烯基]-吡啶 134-135 4-[2-(6-甲基-口比啶-2-基)-乙烯基]苯胺 147-148 2-[2-(3,5-二氯-苯基)-乙烯基]-6-甲基-吡啶-3-醇 218-220 6-[2-(3,5-二氯-苯基)-乙烯基]-2-甲基-吡啶-3-醇 286分解 2-[2_(3,5-二氯-苯基)-乙烯基]-吡啶-3-醇 240-242 2-[2_(6·氯苯並[1,3 ]二oxol-5-基)-乙烯基]各甲基-吡啶 131-132 2-[2-(2,3-二氟-苯基)-乙晞基]-6-甲基-吡啶 55-56 2-[2-(3,4-二氯-苯基)-丙烯基]-6-甲基-吡啶 黃色油 2_[2-(3,5-雙-三氟甲基-苯基)-乙烯基]-6-甲基-吡啶 85-86 醋酉父2-甲氧基-6-[2-(6-甲基比η足·,2-基)-乙 >希基]-冬基酉旨 黃色油 2-甲氧基-6-[2-(6-甲基·吡啶-2-基)-乙烯基]-酚 118-120 2-甲基-6-[2_(2,3,6-三氟-苯基)-乙烯基]-吡啶 59-62 2_[2-(4-氟-3-三氟曱基-苯基)-乙烯基]-6-甲基-吡啶 黃色油 2-甲基-6-(2,3,6-三氟-苯基乙炔基)-吡啶 93-94 醋酸4-氯-2-[2-(6_甲基-吡啶-2·基)-乙晞基]-苯基酯 醋酸2,6-二-第三丁基-4-[2-(6-甲基4比啶-2-基)-乙烯基]· 127-128 (請先閱讀背面之注意事項再填寫本頁 -30- 本紙張尺度適用中國國家標準(CNS ) A4規格(210X 297公釐) 544448 A7 B7 Λ 五 發明説明(28 經滴部中央榡準局員工消費合作社印製 苯基酯 3-ί 6-甲基-外1:。定-2-基-乙块基)苯甲胺 187-189 醋酸4-溴-2-甲氣基甲基比咬冬基)-乙烯基]苯基酯 151-153 2-(6-氣-笨並[1,3]二氧基-5·基乙炔基)-6_甲基-外匕啶 105-106 淡ί冢色晶體 2-f2-(3,5-二氢-笨基)-乙晞基]各甲氧基-6-甲基^比啶 127-129 2·『2-ί3 二氣-策基V乙烯基]·3·甲氧基-吡啶 111-113 5·疊氮基2-[2-(6-甲基比啶_2_基)_乙烯基l·酉分 143分解 2-[2-(吡啶-3-基)乙炔基]-6-甲基^比啶 淡黃色晶體 60-61 Ν-{3-[2-(6-甲基比症-2-基)-乙細基]-苯基卜丁二酸 212-213 1-第三丁基-3·ί3-丨2-(6-甲基-吡啶-2-基)-乙烯基]-苯基}-尿素 191-192 5-({3-[2-(6-甲基-竹匕咬-2-基)-乙細基]-苯基月$基}-甲基)-7-硝 基-1,4-二氮^奎u惡淋-2,3-二酉同 250分解 四氫唉喃-2-獲酸丨3-[2-(6-曱基-p比淀-2-基)-乙、^市基]-苯基} -S&胺 160-161 (M3-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯基胺基甲醯[2-苯基-乙基)_胺基甲酸第三丁酯 ({3-[2-(6_甲基-被啶-2-基)-乙烯基]-苯基胺基甲醯卜甲基)-胺 基曱酸第三丁酯 一乙基-{3·[2-(6-甲基4比呢-2-基)-乙細基]-苯基丨-胺 217分解 乙基-{3 - [2-(6-甲基-口比啶-2-基)·乙晞基]-苯基卜胺 225分解 乙基]3-[2·(6-甲基-吡啶-2-基)-乙烯基]-苯基卜胺 183分解 2_(2·乙氧基-3,6_二氟苯基乙炔基)-6-甲基吡啶 黃色油 -二氟-苯基乙炔基)-6-甲基-,比啶 黃色油 1(3-氟-苯基乙块基)-6-甲基-吡啶 26-28 二甲基-苯基)-乙烯基]-6·甲基^比啶 56-57 _Η^(3,4-二甲氧基-笨基)-乙烯基1-6-曱基·吡啶 55-56 -31 (請先閲讀背面之注意事項再填寫本頁) 一裝· ‘度適用中國國家標準 (CNS ) A4規格(210X 297公釐) 544448 A7 B7 五、發明説明() 經满部中央標準局員工消費合作社印顰 2-胺基-N-丨3-[2-(6-甲基·欢啶-2_基)-乙烯基]-苯基卜乙醯胺 105 2-胺基-N-丨4-[2-(6-甲基-吡啶-2-基)-乙烯基]-苯基卜乙醯胺 217-219 分解 1 -[ 1 -({2-[2-(2-氣-苯基)-乙烯基]-6-甲基-吡啶-3-基氧基卜乙醯 基户派淀-4-基]-咪。坐燒-2-酮 非晶狀泡沫 1 - {4-[2-(6•甲基^比啶-2-基)-乙烯基]-苯基胺基卜乙基)-膦酸二 甲酯 2-[2-(2-曱氧基-苯基)-乙烯基]-6-甲基^比啶 129-130 2-(3-乙氧基-4-氟-苯基乙炔基)-6-甲基-吡啶 82-83 2-(3-氣-苯基乙块基)-6-甲基-口比呢 57-59 1-(3 比淀-2-基乙決基-秦基)-乙細明 48-51 4-氯-2-[2-(6-甲基-吡啶-2-基)-乙烯基]-酚 256-260 4-溴-2-甲氧基-6-[2-(6-甲基^比啶-2-基)-乙烯基]-酚 121-123 2-甲基-6-間-甲苯基乙炔基-吡啶 57-58 2-(2,5·二氟-苯基乙炔基)-6-甲基^比啶 49-50 2-(3,5-二曱基-苯基乙块基)-6-甲基-吡啶 黃色油 2_[2_(3,5-二溴-苯基乙烯基)-0-甲基-吡啶 68-70 2-甲基-6-[2-( 口密症-5-基)-乙炔:基]-¾匕症 110-112 (2-{2-[2-(3-氯-苯基)-乙烯基]-6-甲基-吡啶-3_基氧基卜乙基)-二甲胺 165-167 醋酸1 - {4-丨2-(6-甲基-吡啶-2-基)-乙烯基]-笨基}乙酯 3-[2-(6-曱基-吡啶-2-基)-乙烯基]-酚 250-251 3 -(6-甲基-吡啶-2-基乙炔基)-苯基胺 129-130 N-[3-(6-甲基-吡啶-2-基乙炔基)-艽基]-2-苯基乙醯胺 133-135 分解 噹吩_2_羧酸[3-(6-曱基-吡啶-2-基乙炔基)-苯基]-醯胺 156-157 分解 2-甲基-6+塞吩-2-基乙炔基]-吡啶 34-36 3-(6-甲基-吡啶-2-基乙炔基)-笨甲酸乙酯 56-58 -------------1T-----Φ (請先閲讀背面之注意事項再填寫本頁) -33- 本紙張尺度適用中國國家標隼(CNS ) A4規格(210X 297公釐) 544448 經滴部中央標準局員工消費合作社印絮 A7 B7 發明説明(31 ) 2-(3,5-二溴-苯基乙块基)-6甲基匕咬 100-101 {2-[2-(2-氯-苯基)-乙烯基]各甲基^比啶-3-基甲基卜二甲基胺 227-229 分解 3- {6-[2-(3-氯-笨基)-乙細基]-2-甲基·说呢·。-基氧》基丨-丙基)_ 二甲基胺 184-186 5_疊氮-4·破-2-[2-(6-甲基4比途-2-基)-乙晞基]酉分 紅色玻璃 2,6-二-第三丁基_4-『2-(6-甲基-吡啶-2-基)乙烯基]-酚 126-127 1-{4-[2-(6-甲基-吡啶-2-基)-乙晞基]苯基卜乙醇 97-99 2-甲基-6-『2-(嘧口定-2-基)-乙烯基]·吡啶 144-145 [3-(6-甲基-吡啶_2_基乙炔基)-苯基]-苯基-甲烯酮 90-100 6-(6-甲基比啶-2-基乙炔基)-3,4-二氫-1H-喹啉-2-酮 189-191 2-(3·{2-[2-(3-氤·苯基)-乙晞基]-6-曱基-吡啶-3-基氧基卜丙 基)-異Μ卜果-1,3-二酬 101-103 3-甲氧基-6-甲基-2-間-甲苯基乙炔基-吡啶 棕色油 醋酸2-[2-(6-甲基4比啶-2-基)-乙綿基]_4_硝基苯基酯 129-131 6-(6-甲基-吡啶-2·基乙炔基)-茚滿-1 -酮 160-165 2-曱基_6-[2-(口瓜口秦-2-基)-乙決基]_u比口足 95-96 N-甲基-Ν·(3-丨4-[2·(6-甲基-吡啶"2-基)-乙晞基]•苯氧基卜丙 基)-乙酿胺 62-70 2-[2-(3,5-雙三氟曱基-苯基)小乙氧基-乙晞基]-6-甲基-吡啶 黃色油 醋酸2-苯基乙、决基^比啶-3-基酯 棕色油 醋酸6-甲基-2-間-甲苯基乙烯基4比啶-3-基酯 综色油 醋酸4-[2_(6-甲基^比啶-2-基)-乙烯基]-2-硝基·苯基酯 91-93 2-[2-(6·甲基-吡啶-2-基)-乙烯基]-4-硝基. 275分解 二甲基-[3-(2·苯基乙炔基-吡啶-3-基氧基)-丙基]-胺 黃色油 二甲基-(3-丨4-[2-(6-甲基-17比淀-2-基)乙缔基]-苯氧基卜 丙基)胺 240-243 1-{4-[2-(6-甲基-吡啶-2-基)-乙晞基]-苯基卜乙烯酮 56-58 --------裝-- (讀先閱讀背面之注意事項再填寫本頁)
、1T _-34- (CNS)A4規格( 210X297公釐) 544448 A7
7 B 五、發明説明(32 ) 經漓部中央標率局員工消費合作社印製 2-(3-氟苯基乙炔基)-喹啉 81-83 醋酸2-甲基-6-笨乙烯基-吡啶-3-基酯 93-96 4-[2·(6·曱基-外匕口定基)-乙晞基1_2-硝基_酉分 141-143 3_乙氧基-4-[2_(6-甲基比啶_2_基)-乙烯基]·2-硝基-酚 175-178 分解 4·(6_甲基比口定_2_基)_乙块基1-2-硝基-紛 184-187 分解 醋酸2-[2-(6_甲基-ρ比口定_2_基)-乙綿基]_6-硝基—苯基酉旨 105-110 分解 二甲基-[3·(6_甲基苯基乙炔基·吡啶·3-基氧基)-丙基]•胺 黃色膠 2_疊氮-4_|>(6-甲基-吡啶基)-乙晞基]-g分 155_157 分解 二甲基-[3-(6·甲基·2·間-甲笨基乙炔基吡啶-3·基氧基)-丙 基]-胺 黃色油 2_(3_甲續BS基-苯基乙块基)-6-甲基-ρ比淀 108-110 分解 3 - {2-[2-(3 -氯·笨基)-乙晞基]-6-甲基-ρ比淀-3 -基氧基卜丙胺 186-189 4_疊氮-Ν·(3-{2-[2_(3-氯-苯基)-乙綿基]-6-甲基比淀-3-基氧 基}-丙基)-2-羥基-苯甲醯胺 99-102分解 3-[3·(3-二甲基月安基-丙氧基)-6-甲基-ρ比咬-2-基乙块基]- 苯甲腈 黃色膠 5-(6·甲基-吡啶-2-基)-乙炔基1-印滿-1-酮 133-134 2-曱基-6-(2,3,5-三氣-苯基乙块基卜口比咬 112-114 2-[2_(6-甲基-北啶-3-基)-乙烯基]各甲基-吡啶 118-119 二甲基-{3-[6-甲基-2-(3-三氟甲基-苯基乙块基)-P比咬-3-基氧 基]-丙基卜胺 黃色膠 2-[2·(6·甲基-吡啶-3-基)-乙炔基]_.3_甲氧基-6·甲基-峨啶氯化 氫鹽 198-199 2-甲基-6-(5,6,7,8-四氫-茶-2-基乙炔基)-吡啶 50-51 3-[2-(3-氯-苯基乙炔基)_6·甲基-吡啶:基氧基]-丙基胺 151-153 (3_丨4_溴_2·甲氡基-6·[2-(6·甲基-吡啶_2·基)-乙烯基]-苯氧基} 丙基)-二甲基-月安 211-215 [6-(3-氟-苯基乙炔基)-ρ比症-2-基]-·二甲基·胺 棕色油 (讀先閱讀背面之注意事項再填寫本頁) -35- 本紙張尺度適用中國國家標擎-(CNS ) A4規格(210X297公釐) 544448 五、 經濟部中央標準局員工消費合作社印繁 A7 __B7 發明説明(35 ) 3-{2-[2-(3-氟-笨基)-乙烯基]-6-甲基-竹1:啶-3-基氧基卜丙-1-醇 86-88 [6-(3-氟-苯基乙炔基)-2·甲基-吡啶-3-基甲基]-二甲基-胺 220-222 2,2-二曱基-丙酸3-[2-(3-氟-苯基乙決基)-6-甲基-吡啶-3-基]- 丙酉旨 黃色油 二-營乱基-冬石典^-^-甲基-吹呢-二-基乙块基彡-酉分 140分解 6_疊氮基-2,4·二碘-3-(6-甲基^比啶-2-基乙炔基)·酚 162分解 4-疊氮基-2-羥基-5-碘-N-[3-(6-甲基-吡啶-2-基乙炔基)-苯基]· 苯甲醯胺 185分解 醋酸3-乙醯氧基甲基-5-(6-甲基-吡啶-2-基乙炔基)-芊基酯 棕色油 (苄基-{[2-(3-氣-苯基乙炔基)-6-甲基-吡啶-3-基氧基]-乙醯 基卜胺基)-乙酸乙酯 棕色油 2-[2-(3-氟苯基)-乙晞基-6-甲基-異菸鹼酸乙酯 76-77 〕-[2_(3-氣苯基乙块基)·6-甲基-峨淀-3_基氧基]-丙-1-酉手 72-74 [3-羥基曱基-5-(6-甲基4啶-2_基乙炔基)-苯基]-甲醇 115-117 (3-{2-[2-(3>二甲基-苯基)-乙烯基]-6甲基-吡啶-3-基氧基}-丙基-二甲基-胺 黃色膠 [4-(4-氣-苯甲廳1基)-喊淀-1-基]-丨6-[2-(3-氟-苯基)-乙締基]-2- 甲基-峨啶-3-基}-甲烯酮 156-158 2_[2·(3·氟-苯基)-乙烯基1-6_曱基-昊菸鹼酸 245-248 {6-[2-(2氯-苯基)-乙烯基]-2-甲基-吡啶_3_基卜4-(4_氟·苯甲醯 基)-喊淀-1-基]-甲烯酮 109-112 2-(3_乙炔基-笨基乙炔基)-6·甲基4匕啶 48-49 (3-{2-[2-(2,6-二氯-苯基)-乙晞基]-6*"甲基基氧基}丙 基)-二甲基胺1化氫鹽 207-210 (3-{2-[2-(2,3·二氯-苯基)-乙烯基]-6-甲基^比啶各基氧基卜丙 基)-二甲基-胺氯化氫鹽 161-169 4-[6-(3-氟苯基乙炔基)-2-甲基^比啶-3-羰基]-哌嗪-1-羧酸第 三丁酯 97-99 [6-(3-氟苯基乙炔基)·2-甲基-外t啶-3-基]-味嗪-1-甲烯酮 250-252 分解 (請先閱讀背面之注意事項再填寫本頁) "Λ I張 紙 一本 -38- (CNS ) A4規格(210 X 297公釐) 544448 經濟部中央標率局貝工消費合作社印製 A7 B7 五、發明説明(36 ) [4-(4-疊氮基-2-羥基-苯甲醯基)-哌嗪-1 -基]各(3 -氟-苯基乙烯 基)-2-甲基· 口比啶-3-基]-甲烯酮 186-188 分解 (3-丨2-[2-(2,4-二氯-苯基)-乙烯基]-6-甲基4匕啶-3-基氧基卜丙 基)-二甲基胺氯化氫鹽 170-176 2-(3-鼠-冬基乙決基)-6-甲基-兴於齡乙酉旨 89-91 2-(3-氟-苯基乙炔基)-6-甲基-異菸鹼酸異丁酯 94-96 2-(3-氟·苯基乙炔基)-6_甲基-異菸鹼酸 231分解 [2-(3-氟-苯基乙炔基)-6-甲基-吡淀-4-基]-甲醇 143-146 [4-(4-氣-苯甲廳基)-味咬>1-基]-[2-(3-氣-苯基乙決基)-6·甲基_ 外匕口定-4_基-甲烯酮 156-158 3-烯丙氧基-2-[2-(3,5-二氯-苯基)-乙烯基]-6-甲基吡啶 105-106 [2-(3-氟-苯基乙块基)-6-甲基比咬-4-基]-嗎4-4-基-甲晞酮 114-116 醋酸3-(6-甲基-吡啶-2-基乙炔基)-苯甲酯 棕色油 [2-(3-氟·苯基乙炔基)-6·甲基-吡啶-4-基甲基]-二甲基_胺 209-212 (3-丨2-[2-(3,5-二氯-苯基)-丙烯基]-6-甲基-吡啶-3-基氧基}-丙 基)-二甲基-胺氯化氫鹽 182-184 2-(3-氟·苯基乙決基)-3-甲氧基-6·甲基-¾匕口定 黃色油 (3-丨2-[2-(3,5-二氣-苯基)-乙烯基]-吡啶-3-基氧基卜丙基)-二 甲基-胺氯化氫鹽 171-174 4-疊氮基-2_羥基-5 _碘-笨基-丨4-[6··( 3 _氟-苯基乙烯基)-2·甲基-吡啶-3-羰基]-哌嗪-1 -基丨甲烯酮 195-200 分解 4-®氣基-Ν-丨3-[2-(3-氣-苯基乙块基)-6-甲基-Ρ比淀-3-基氧 基]-丙基卜2-經基-5-碘-苯甲醯胺 142-150 分解 4-(2·吡啶-2-基-乙烯基)-苯甲酸乙酯 100-102 (3·{2-[2-(4-氯-苯基)-乙晞基]-6-甲基-说啶-3-基氧基卜丙基)- 二甲基-胺氯化氫鹽 159-171 [3-(6_甲基-外(:淀-2-基乙块基)-苯基]-曱醇 43-45 6-(3_氟-苯基乙块基)-於驗酸第三丁酉旨 96-98 (3-{2-[2-(3,4_二氯-苯基)-乙晞基]-6-甲基-吡啶-3-基氧基}-丙 174-177 (讀先閱讀背面之注意事項再填寫本頁) _____ -39- 本纸張尺度適用中國國家標準(CNS ) A4規格(21〇X297公釐) 544448 五、發明説明(37 A7 B7 基)-二甲基-胺氯化氫鹽 昊-2-苯基-乙晞基)-4-甲基-17密淀 黃色油 6-(3-氟-笨基乙块^基)-於驗酸 223分解 [4_(4_氟-苄醯基)-喊啶小基]-[6-(3-氟-苯基乙块基)-吡啶-3-基]-甲烯酿] 136.0-139.0 2-(2-第三丁氧基-3,6-二氟-苯基乙炔基)-6-甲基-吡啶 72.0-74.0 2-甲基-6-丨2-(2,4,5-三氟-苯基)-乙烯基]-吡啶 74-76 2-甲基-6_[2-(2,3,4-三氟-苯基)-乙晞基]叶匕口定 79-82 3-(6-甲基·吡啶-2-基乙炔基)-酚 142-144 2-曱基-6-[2-(3,4,5-^氣-苯基)-乙蹄基]-叶匕17足 74-76 2_(3-曱氧基-苯基乙块基)-6-甲基-外匕咬 55-57 2-甲基-6-(2,3,4-三氟-苯基乙炔基)-吡啶 104-106 (讀先閱讀背面之注意事項再填寫本頁) 經漓部中央標率局員工消費合作社印繁 ___ - 40 - 本紙張尺度適用中國國家標隼(CNS ) A4規格(210X297公釐)

Claims (1)

  1. 544448第術丨I·7號專利申請案 中文申請專利範圍修正本(91年7月) 、申請幸痛HI------------! 丨公告本j 丨 j ,一 ~ ' 一 1. 一種式I化合物 I補充 本"\丨年七巧
    (I), 其中, X 代表伸乙块基, Ri是(C^4)烷基、(Cu)烷氧基、氰基、乙炔基或 (C丨·4)烷基胺基, R2是氫,經基、複基、(C 1 ·4)垸氧基馥基、二(C 1 ·4) 虎基胺基甲基、4-(4 -氟-爷8¾基)-來症-1-基·幾 基、4 -第三丁氧基羰基哌嗪-1-基-羧基、4-(4 -疊 氮基-2 -羥基芊醯基)-哌嗪-1 -基-羧基或4 - ( 4 -疊氮 基-2 -護基-3 -碘-苄醯基)-哌嗪-1 -基-羧基’ R3是氫、(Cl -4)烷基、羧基、(Ci _4)烷氧基羰基、 (Ci·4)烷基胺甲醯基、羥基(Ci·4)烷基、二(C〖.4) 烷基胺基甲基、嗎啉代羰基或4 - (4 -氟芊S&基)-哌 啶-1 -基-羧基, R4是氫、羥基、羧基、(C2-5)烷醯氧基、(Ci“)境氧 基羰基、胺基(C丨_4)烷氧基、二(C丨-4)虎基胺基 (Ci·4)烷氧基、二(Ci·4)燒基胺基(Cm)淀基或羥 基(C卜4)烷基,且 R 5是下式基團 本紙張尺度適用中國國家標準(CNS) A4規格(210 X 297公董) 544448 A8 B8 C8
    六、申請專利範圍
    其中, L和Rb分別是氫、自素、硝基、氰基、(Ci 4)烷基、 (Cl·4)烷氧基、三氟甲基、三氟甲氧基或(C25)炔 基, I是氫、氟、氯、溴、羥基、(cU4)烷基、(c2-5)烷 酿氧基、(Ci-4)烷氧基或氰基,且 Rd是氫、鹵素或(c14)烷基, 其限制條件為,於其中R2、R3及R4為氫之化合物中, 當Ri為甲基時,Rs係不同於苯基、甲基苯基、6•甲 基吡啶-2-基及3-甲氧基苯基,其為自由形式或醫藥上 可接受的鹽之形式。 2·根據申請專利範圍第i項之化合物,其中R5係不同於視 情況經取代之苯基,其為自由形式或醫藥上可接受的鹽 之形式。 3·根據申請專利範圍第2項之化合物,其中r5係視情況經 取代之叶b違-3 -基’其為自由形式或醫藥上可接受的鹽 之形式。 4.根據申請專利範圍第1項之化合物,其為2 - [ 2 - ( p比咬· 3 · 基)乙決基]-6 -甲基-吡啶,其為自由形式或醫藥上可接 本紙張足度適用中國國家標準(CNS) A4規格(210 X 297公釐) 8 8 8 8 A B c D 544448 六、申請專利範圍 受的鹽之形式。 5. 一種用於治療與谷胺酸訊息傳遞不規則有關的病症及於 與完全或部分由mGluR5所媒介的神經系統病症之醫藥 組成物,其包含作為醫藥活性成份之根據申請專利範圍 第1至4項中任一項之呈自由形式或醫藥上可接受的鹽之 形式之化合物,及慣用的醫藥賦形劑。 -3- 本紙張尺度適用中國國家標準(CNS) A4規格(210 X 297公釐)
TW087110887A 1997-07-11 1998-07-06 Pyridine derivatives TW544448B (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US89068997A 1997-07-11 1997-07-11
US89169197A 1997-07-11 1997-07-11

Publications (1)

Publication Number Publication Date
TW544448B true TW544448B (en) 2003-08-01

Family

ID=27128958

Family Applications (1)

Application Number Title Priority Date Filing Date
TW087110887A TW544448B (en) 1997-07-11 1998-07-06 Pyridine derivatives

Country Status (26)

Country Link
US (1) US6656957B1 (zh)
EP (1) EP0998459B1 (zh)
JP (1) JP3481208B2 (zh)
KR (1) KR20010021712A (zh)
CN (1) CN1203060C (zh)
AR (1) AR016314A1 (zh)
AT (1) ATE393145T1 (zh)
AU (1) AU738973B2 (zh)
BR (1) BR9811685A (zh)
CA (1) CA2295678C (zh)
DE (1) DE69839398T2 (zh)
ES (1) ES2308811T3 (zh)
HU (1) HUP0004225A3 (zh)
ID (1) ID23889A (zh)
IL (1) IL133904A0 (zh)
MY (1) MY119800A (zh)
NO (1) NO20000124L (zh)
NZ (1) NZ502210A (zh)
PE (1) PE97799A1 (zh)
PL (1) PL343865A1 (zh)
PT (1) PT998459E (zh)
RU (1) RU2203889C2 (zh)
SK (1) SK232000A3 (zh)
TR (1) TR200000059T2 (zh)
TW (1) TW544448B (zh)
WO (1) WO1999002497A2 (zh)

Families Citing this family (102)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ID29095A (id) * 1998-10-02 2001-07-26 Novartis Ag Cs Antagonis mglur5 untuk pengobatan rasa sakit dan kegelisahan
WO2000064430A1 (fr) * 1999-04-23 2000-11-02 Sumitomo Pharmaceuticals Co., Ltd. Inhibiteurs de l'apoptose
FR2793245B1 (fr) * 1999-05-05 2002-10-11 Adir Nouveaux composes pyridiniques ou piperidiniques substitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6660753B2 (en) 1999-08-19 2003-12-09 Nps Pharmaceuticals, Inc. Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
US6774138B2 (en) 1999-08-31 2004-08-10 Merck & Co., Inc. Thiazolyl(pyridyl)ethyne compounds
CA2383524C (en) * 1999-08-31 2010-09-28 Merck & Co., Inc. Thiazolyl alkynyl compounds and methods of use thereof
GB0005700D0 (en) * 2000-03-09 2000-05-03 Glaxo Group Ltd Therapy
US7205297B2 (en) 2000-07-24 2007-04-17 Krenitsky Pharmaceuticals, Inc. Substituted 5-alkynyl pyrimidines having neurotrophic activity
CN1257894C (zh) 2000-12-04 2006-05-31 弗·哈夫曼-拉罗切有限公司 作为谷氨酸受体拮抗剂的苯基乙烯基或苯基乙炔基衍生物
GB0103045D0 (en) * 2001-02-07 2001-03-21 Novartis Ag Organic Compounds
NZ527691A (en) * 2001-02-21 2007-01-26 Nps Pharma Inc Heteropolycyclic compounds and their use as metabotropic glutamate receptor antagonists
US8124625B2 (en) 2001-09-14 2012-02-28 Shionogi & Co., Ltd. Method of enhancing the expression of apolipoprotein AI using olefin derivatives
CA2462442A1 (en) * 2001-10-12 2003-04-24 Warner-Lambert Company Llc Alkyne matrix metalloproteinase inhibitors
US6951875B2 (en) * 2001-10-29 2005-10-04 Hoffmann-La Roche Inc. Conjugated aromatic compounds with a pyridine substituent
GB0128996D0 (en) 2001-12-04 2002-01-23 Novartis Ag Organic compounds
WO2003093236A1 (en) * 2002-05-02 2003-11-13 Euro-Celtique, S.A. 1-(pyrid-2-yl)-piperazine compounds as metabotropic glutamate receptor inhibitor
AU2003253149A1 (en) * 2002-08-13 2004-02-25 Warner-Lambert Company Llc 3,4-dihydroquinolin-2-one, 5,6-fused oxazin-3-one, and 5,6-fused thiazin-3-one derivatives as matrix metalloproteinase inhibitors
EP1539749A4 (en) * 2002-09-13 2007-06-13 Merck & Co Inc BY CONDENSED HETEROBICYCLOGRUPPEN SUBSTITUTED PHENYL COMPOUNDS AS METOBOTROPE GLUTAMATE-5 MODULATORS
CA2503245A1 (en) * 2002-10-24 2004-05-06 Merck & Co., Inc. Alkyne derivatives as tracers for metabotropic glutamate receptor binding
US7452911B2 (en) 2002-10-31 2008-11-18 Boehringer Ingelheim Pharma Gmbh & Co. Kg Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds
DE10250708A1 (de) * 2002-10-31 2004-05-19 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
US7351719B2 (en) 2002-10-31 2008-04-01 Boehringer Ingelheim Pharma Gmbh & Co. Kg Amide compounds having MCH-antagonistic activity and medicaments comprising these compounds
ITMI20030151A1 (it) * 2003-01-30 2004-07-31 Recordati Ind Chimica E Farma Ceutica S P A Uso di antagonisti selettivi del recettore mglu5 per il trattamento di disfunzioni neuromuscolari del tratto urinario inferiore.
EP2028180A1 (en) * 2003-03-04 2009-02-25 ADDEX Pharma S.A. Novel aminopyridine derivatives as mGluR5 antagonists
RU2333200C2 (ru) 2003-03-07 2008-09-10 Астеллас Фарма Инк. Азотсодержащие гетероциклические производные, содержащие 2,6-дизамещенный стирил
TWI292318B (en) 2003-03-10 2008-01-11 Hoffmann La Roche Imidazol-4-yl-ethynyl-pyridine derivatives
UA80888C2 (en) * 2003-06-05 2007-11-12 Hoffmann La Roche Imidazole derivatives as glutmate receptor antagonists
US7531529B2 (en) 2003-06-05 2009-05-12 Roche Palo Alto Llc Imidazole derivatives
MXPA05013233A (es) * 2003-06-12 2006-03-09 Hoffmann La Roche Derivados de imidazol heteroaril-substituidos como antagonistas del receptor de glutamato.
WO2005007641A1 (en) * 2003-07-03 2005-01-27 Euro-Celtique S.A. 2-pyridine alkyne derivatives useful for treating pain
US7091222B2 (en) * 2003-07-03 2006-08-15 Hoffmann-La Roche Inc. Imidazole derivatives
AR046276A1 (es) 2003-10-07 2005-11-30 Renovis Inc Derivados de amida como ligandos de canales ionicos y composiciones farmaceuticas y metodos que los utilizan.
WO2005044267A1 (en) * 2003-10-31 2005-05-19 Astrazeneca Ab Alkynes ii
JP2007509934A (ja) * 2003-10-31 2007-04-19 アストラゼネカ アクチボラグ アルキン類iii
CA2549967A1 (en) * 2003-10-31 2005-05-19 Astrazeneca Ab Alkynes i
GB0325956D0 (en) * 2003-11-06 2003-12-10 Addex Pharmaceuticals Sa Novel compounds
US7592373B2 (en) 2003-12-23 2009-09-22 Boehringer Ingelheim International Gmbh Amide compounds with MCH antagonistic activity and medicaments comprising these compounds
DE102004017934A1 (de) 2004-04-14 2005-11-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
US20050245529A1 (en) * 2004-04-14 2005-11-03 Boehringer Ingelheim International Gmbh Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds
DE102004017930A1 (de) * 2004-04-14 2005-11-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
US7524862B2 (en) 2004-04-14 2009-04-28 Boehringer Ingelheim International Gmbh Alkyne compounds with MCH antagonistic activity and medicaments comprising these compounds
DE102004017935A1 (de) * 2004-04-14 2005-11-03 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Alkin-Verbindungen mit MCH-antagonistischer Wirkung und diese Verbindungen enthaltende Arzneimittel
JP4690395B2 (ja) 2004-06-01 2011-06-01 エフ.ホフマン−ラ ロシュ アーゲー mGlu5レセプターアンタゴニストとしてのピリジン−4−エチニル−イミダゾール及びピラゾール
NZ552031A (en) * 2004-06-16 2009-06-26 Wyeth Corp Amino-5,5-diphenylimidazolone derivatives for the inhibition of beta-secretase
JP2008503460A (ja) * 2004-06-16 2008-02-07 ワイス β−セクレターゼのインヒビターとしてのジフェニルイミダゾピリミジンおよびイミダゾールアミン
GB0413605D0 (en) * 2004-06-17 2004-07-21 Addex Pharmaceuticals Sa Novel compounds
JP2008526966A (ja) 2005-01-14 2008-07-24 ワイス β−セクレターゼの阻害のためのアミノ−イミダゾロン
AU2006205920B2 (en) 2005-01-14 2012-11-15 F. Hoffmann-La Roche Ag Thiazole-4-carboxamide derivatives as mGluR5 antagonists
AU2006211159A1 (en) * 2005-02-01 2006-08-10 Wyeth Amino-pyridines as inhibitors of beta-secretase
BRPI0606902A2 (pt) * 2005-02-14 2009-07-28 Wyeth Corp composto; método para o tratamento de uma doença ou distúrbio associado a atividade excessiva de bace em um paciente que dele necessite; método para modular a atividade de bace; composição farmacêutica
US7576099B2 (en) 2005-02-28 2009-08-18 Renovis, Inc. Amide derivatives as ion-channel ligands and pharmaceutical compositions and methods of using the same
BRPI0607583A2 (pt) * 2005-03-04 2009-09-15 Hoffmann La Roche derivados de piridin-2-carboxamida como antagonistas mglur5, método para sua preparação, medicamento contendo os mesmos, bem como uso relacionado aos referidos compostos
GB0508319D0 (en) * 2005-04-25 2005-06-01 Novartis Ag Organic compounds
WO2007005404A1 (en) * 2005-06-30 2007-01-11 Wyeth AMINO-5-(6-MEMBERED)HETEROARYLIMIDAZOLONE COMPOUNDS AND THE USE THEREOF FOR ß-SECRETASE MODULATION
TW200738683A (en) * 2005-06-30 2007-10-16 Wyeth Corp Amino-5-(5-membered)heteroarylimidazolone compounds and the use thereof for β-secretase modulation
FR2889187B1 (fr) * 2005-07-28 2007-09-07 Servier Lab Nouveaux composes 1,1-pyridinyloxycyclopropanamines polysusbstitues, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
FR2889188B1 (fr) * 2005-07-28 2007-09-07 Servier Lab Nouveaux composes 1,1-pyridinylaminocyclopropanamines polysubstitues, leur procede de preparation et les compositions phamaceutiques qui les contiennent
TW200730523A (en) * 2005-07-29 2007-08-16 Wyeth Corp Cycloalkyl amino-hydantoin compounds and use thereof for β-secretase modulation
US7531541B2 (en) * 2005-09-20 2009-05-12 Vanderbilt University Partial mGluR5 antagonists for treatment of anxiety and CNS disorders
BRPI0616757A2 (pt) * 2005-09-26 2011-06-28 Wyeth Corp composto da fórmula i; processo para o tratamento de uma doença ou de um distúrbio associado com a atividade excessiva de bace; processo para a modulação da atividade de bace; processo para o tratamento da doença de alzheimer; e composição farmacêutica
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
CA2634037A1 (en) * 2005-12-19 2007-07-12 Wyeth 2-amino-5-piperidinylimidazolone compounds and use thereof for .beta.-secretase modulation
DE102005062985A1 (de) * 2005-12-28 2007-07-05 Grünenthal GmbH Substituierte bis(hetero)aromatische N-Ethylpropiolamide und ihre Verwendung zur Herstellung von Arzneimitteln
WO2007100536A1 (en) * 2006-02-24 2007-09-07 Wyeth DIHYDROSPIRO[DIBENZO[A,D][7]ANNULENE-5,4'-IMIDAZOL] COMPOUNDS FOR THE INHIBITION OF β-SECRETASE
NZ570887A (en) 2006-03-30 2011-05-27 Univ Pennsylvania Styrylpyridine derivatives and their use for binding and imaging amyloid plaques
BRPI0710328A2 (pt) * 2006-05-08 2011-08-09 Ariad Pharma Inc composto da fórmula i, um tautomer da mesma, ou um sal farmaceuticamente aceitável, hidrato ou outro solvato do mesmo e método para o tratamento de cáncer em um mamìfero necessitado do mesmo e composição
US7700606B2 (en) * 2006-08-17 2010-04-20 Wyeth Llc Imidazole amines as inhibitors of β-secretase
MX2009003102A (es) * 2006-09-21 2009-04-01 Wyeth Corp INDOLILALQUILPIRIDIN-2-AMINAS PARA LA INHIBICION DE ß-SECRETASA.
CA2670116C (en) 2006-11-22 2015-03-10 Seaside Therapeutics, Llc Methods of treating mental retardation, down's syndrome, fragile x syndrome and autism
AU2007336369B2 (en) 2006-12-21 2013-01-17 F. Hoffmann-La Roche Ag Polymorphs of a mGluR5 receptor antagonist
UA109896C2 (xx) * 2007-02-22 2015-10-26 Похідні імінопіридину та їх застосування як мікробіоцидів
DK2124562T3 (en) 2007-03-09 2016-08-01 Second Genome Inc BICYCLOHETEROARYLFORBINDELSER AS P2X7 modulators and uses thereof
CN101679261A (zh) * 2007-03-09 2010-03-24 阿斯利康(瑞典)有限公司 哌嗪和哌啶mGluR5增效剂
PE20090160A1 (es) * 2007-03-20 2009-02-11 Wyeth Corp COMPUESTOS AMINO-5-[4-(DIFLUOROMETOXI)FENIL SUSTITUIDO]-5-FENILIMIDAZOLONA COMO INHIBIDORES DE ß-SECRETASA
AR065814A1 (es) * 2007-03-23 2009-07-01 Wyeth Corp Derivados de 5-fenilimidazolona,inhibidores de beta-secretasa,composiciones farmaceuticas que los contienen y usos para prevenir y/o tratar trastornos asociados a niveles beta-amiloides elevados.
US8853392B2 (en) * 2007-06-03 2014-10-07 Vanderbilt University Benzamide mGluR5 positive allosteric modulators and methods of making and using same
WO2008151184A1 (en) * 2007-06-03 2008-12-11 Vanderbilt University Benzamide mglur5 positive allosteric modulators and methods of making and using same
GB0713686D0 (en) 2007-07-13 2007-08-22 Addex Pharmaceuticals Sa New compounds 2
US8034806B2 (en) * 2007-11-02 2011-10-11 Vanderbilt University Bicyclic mGluR5 positive allosteric modulators and methods of making and using same
MX2011006680A (es) 2008-12-24 2011-07-12 Astrazeneca Ab Compuestos etanaminicos y su uso para tratar la depresion.
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
CN102459185B (zh) * 2009-04-20 2015-06-03 田边三菱制药株式会社 新型甲状腺激素β受体激动剂
AR080055A1 (es) 2010-02-01 2012-03-07 Novartis Ag Derivados de pirazolo-[5,1-b]-oxazol como antagonistas de los receptores de crf -1
WO2011092293A2 (en) 2010-02-01 2011-08-04 Novartis Ag Cyclohexyl amide derivatives as crf receptor antagonists
JP5748777B2 (ja) 2010-02-02 2015-07-15 ノバルティス アーゲー Crf受容体アンタゴニストとしてのシクロヘキシルアミド誘導体
WO2011109398A2 (en) 2010-03-02 2011-09-09 President And Fellows Of Harvard College Methods and compositions for treatment of angelman syndrome and autism spectrum disorders
US8420661B2 (en) * 2010-04-13 2013-04-16 Hoffmann-La Roche Inc. Arylethynyl derivatives
US20110294879A1 (en) 2010-05-28 2011-12-01 Xenoport, Inc. Method of treatment of fragile x syndrome, down's syndrome, autism and related disorders
US20120016021A1 (en) 2010-07-15 2012-01-19 Xenoport, Inc. Methods of treating fragile x syndrome, down's syndrome, autism and related disorders
US8772300B2 (en) * 2011-04-19 2014-07-08 Hoffmann-La Roche Inc. Phenyl or pyridinyl-ethynyl derivatives
US8546416B2 (en) 2011-05-27 2013-10-01 Novartis Ag 3-spirocyclic piperidine derivatives as ghrelin receptor agonists
AU2013255458A1 (en) 2012-05-03 2014-10-09 Novartis Ag L-malate salt of 2, 7 - diaza - spiro [4.5 ] dec- 7 - yle derivatives and crystalline forms thereof as ghrelin receptor agonists
SG11201501375YA (en) * 2012-10-18 2015-03-30 Hoffmann La Roche Ethynyl derivatives as modulators of mglur5 receptor activity
KR101684816B1 (ko) * 2012-10-18 2016-12-20 에프. 호프만-라 로슈 아게 mGluR5 수용체 활성의 조절제로서 에틴일 유도체
UA116023C2 (uk) 2013-07-08 2018-01-25 Ф. Хоффманн-Ля Рош Аг Етинільні похідні як антагоністи метаботропного глутаматного рецептора
EP2853565A1 (en) 2013-09-27 2015-04-01 Consejo Superior De Investigaciones Científicas Glutamate receptor photomodulators
CN106146391A (zh) * 2015-04-15 2016-11-23 中国科学院上海药物研究所 5-芳香炔基取代的苯甲酰胺类化合物及其制备方法、药物组合物和用途
EP3411010A1 (fr) * 2016-02-03 2018-12-12 Galderma Research & Development Nouveaux composes propynyl bi-aromatiques, compositions pharmaceutiques et cosmetiques les contenant et utilisations
US10449186B2 (en) * 2017-06-21 2019-10-22 University Of Kentucky Research Foundation Phenylethynyl-substituted benzenes and heterocycles for the treatment of cancer
WO2019025931A1 (en) 2017-07-31 2019-02-07 Novartis Ag USE OF A MUSSEL FOR REDUCING THE USE OF COCAINE OR FOR PREVENTING A RECHUTE IN THE USE OF COCAINE
CN107400256B (zh) * 2017-08-14 2019-04-19 深圳市精研科洁科技股份有限公司 一种抗紫外线塑料添加剂的制备方法
WO2023122212A2 (en) 2021-12-21 2023-06-29 Southern Research Institute Substituted phenyl ethynyl pyridine carboxamides as potent inhibitors of sars virus

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4006240A (en) * 1975-03-19 1977-02-01 Ho Andrew K S Alcohol aversion process by enzyme inhibition
NO174506B (no) * 1984-10-30 1994-02-07 Usv Pharma Corp Analogifremgangsmaate ved fremstilling av terapeutisk aktive forbindelser
EP0334119B1 (en) * 1988-03-21 1993-06-16 Boehringer Ingelheim Pharmaceuticals Inc. Compounds for inhibiting the biosynthesis of lipoxygenase-derived metabolites of arachidonic acid
US5013744B1 (en) * 1989-12-29 1994-09-20 Allegran Inc Acetylenes disubstituted with a pyridinyl group and a substituted phenyl group having retinoid like activity
JPH05500781A (ja) * 1990-08-08 1993-02-18 ゼネラル・エレクトリック・カンパニイ 不織フェルトを使った繊維強化熱可塑性合成樹脂の製造方法
GB9515412D0 (en) * 1995-07-27 1995-09-27 Pharmacia Spa 2-(4-substituted)-benzylamino-2-methyl-propanamide derivatives
JPH11509847A (ja) * 1995-07-31 1999-08-31 ノボ ノルディスク アクティーゼルスカブ ヘテロ環式化合物、それらの調製及び使用
IT1276153B1 (it) * 1995-11-17 1997-10-27 Roberto Pellicciari Derivati di glicina ad attivita' antagonista dei recettori metabotropi del glutammato

Also Published As

Publication number Publication date
BR9811685A (pt) 2000-09-19
CN1262676A (zh) 2000-08-09
DE69839398D1 (de) 2008-06-05
PT998459E (pt) 2008-07-31
TR200000059T2 (tr) 2000-06-21
JP3481208B2 (ja) 2003-12-22
CA2295678A1 (en) 1999-01-21
KR20010021712A (ko) 2001-03-15
CN1203060C (zh) 2005-05-25
ES2308811T3 (es) 2008-12-01
IL133904A0 (en) 2001-04-30
NO20000124L (no) 2000-03-02
PE97799A1 (es) 1999-11-08
DE69839398T2 (de) 2009-05-28
JP2001509504A (ja) 2001-07-24
WO1999002497A2 (en) 1999-01-21
CA2295678C (en) 2010-04-13
HUP0004225A2 (hu) 2001-05-28
WO1999002497A3 (en) 1999-04-01
HUP0004225A3 (en) 2001-06-28
SK232000A3 (en) 2000-06-12
EP0998459B1 (en) 2008-04-23
ATE393145T1 (de) 2008-05-15
US6656957B1 (en) 2003-12-02
NO20000124D0 (no) 2000-01-10
EP0998459A2 (en) 2000-05-10
AR016314A1 (es) 2001-07-04
RU2203889C2 (ru) 2003-05-10
PL343865A1 (en) 2001-09-10
NZ502210A (en) 2002-07-26
AU8974398A (en) 1999-02-08
ID23889A (id) 2000-05-25
MY119800A (en) 2005-07-29
AU738973B2 (en) 2001-10-04

Similar Documents

Publication Publication Date Title
TW544448B (en) Pyridine derivatives
JP5753927B2 (ja) 有機化合物
JP7074903B2 (ja) イミダゾピリダジン化合物
SG175925A1 (en) Aryl pyridine as aldosterone synthase inhibitors
JPH08501801A (ja) スチリル誘導体,その調製品とpde‐iv阻害剤としての使用
EP2935253A2 (en) Novel heterocyclic compounds as bromodomain inhibitors
JP2011504505A (ja) 肺および心血管障害を治療するためのビアリールpde4抑制剤
CN101835752A (zh) 用于治疗癌症和银屑病的杂环酰胺
TW200815402A (en) 1,2-dihydropyridine compounds, process preparation of the same and use thereof
TW200825072A (en) Soluble epoxide hydrolase inhibitors
TW200404541A (en) Pyridine derivatives
US9475802B2 (en) Inhibitors of viral replication, their process of preparation and their therapeutical uses
TW200408621A (en) Compounds
TW201018466A (en) Pyridinyl modulators of γ-secretase
JP2001512486A (ja) アリール置換オレフィン型アミン化合物を含む医薬組成物
IE911913A1 (en) Benzoic acid derivatives for treating leukotriene-related¹diseases
JPH0334967A (ja) ブタン化合物またはその塩およびその医薬用途
IE911938A1 (en) Amide linked pyridyl-benzoic acid derivatives for treating¹leukotriene-related diseases
JP2016514714A (ja) 尿素誘導体及びその脂肪酸結合タンパク質(fabp)阻害剤としての使用
JPS62135473A (ja) イミダゾ−ル縮合複素環化合物
TW393487B (en) Guanidine derivatives
CZ200068A3 (cs) Deriváty pyridinu a farmaceutický prostředek, který je obsahuje
WO1996019454A1 (fr) Derives de pyridylalkyle-phenyl-sulfone et preparation medicinale les contenant

Legal Events

Date Code Title Description
GD4A Issue of patent certificate for granted invention patent
MM4A Annulment or lapse of patent due to non-payment of fees